ClinicalTrials.gg
WithdrawnNCT06103734Updated Jan 13, 2026

A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants

A Phase 3 interventional study of Zavegepant 10 mg and Placebo - Control 1 in Migraine, sponsored by Pfizer. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Strategic decision to cancel the study based on adjusted clinical development plan.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing zavegepant in Migraine Disorders — 4 open to participants now, 4 under way, none of them phase 3. zavegepant · Migraine Disorders.

Enrollment
12th of 12
0 · median 225
Started
2025
with 2 others
Phase 3
3 of 12
none open now
Registered
7th of 12
by date
Lead sponsor
8 of 12
Pfizer

Among the 12 studies testing zavegepant in Migraine Disorders, this one is the 12th largest by enrollment, is one of 3 that started in 2025, is one of 3 in phase 3, and was the 7th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

4 of the 12 studies testing zavegepant in Migraine Disorders are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About zavegepant

zavegepant: first FDA approval 2023 (ZAVZPRET). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing zavegepant in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of this study to show that zavegepant 10 milligrams given through the nose provides:

  • freedom from pain, 2 hours after taking the medicine for the first migraine attack.
  • consistent freedom from pain, 2 hours after taking the medicine across 4 separate migraine attacks.

This study is seeking participants who:

  • are 18 years of age or older.
  • have migraine attacks present for at least 1 year with age onset before 50 years old.
  • have migraine attacks, on average, lasting about 4 to 72 hours if not treated.
  • have 3 to 8 attacks per month but less than15 headache days per month.

If the participant is fit to take part in the study, the participant will receive either the study medicine zavegepant or placebo. A placebo looks like zavegepant but does not contain active ingredients. The study medicine will be given using nasal spray device containing a single amount of zavegepant or matching placebo.

The participants will be instructed to take the study medicine at home if participants have a migraine headache which reaches moderate or severe pain intensity. The participants are expected to treat up to 4 migraines of moderate to severe intensity.

After taking the study medicine, the participant is not allowed to take any other medications for at least 2 hours after taking the study medicine or placebo. Participant can take other medicines after the 2 hours if the migraine is still present. The participant is expected to record on a paper log all medications taken throughout the study.

The study duration is around 26 weeks. This includes a 28-day screening window, up to 20 weeks of treatment period, and a follow up visit at about 4 weeks after taking the study medicine the last time.

The participant is expected to come into the study center up to 4 times. There will be up to 3 telephone contacts including one after taking the study medicine the first time or Month 1 whichever comes first, at Month 3 if the participant is still in the study, and a safety follow-up.

During the study, the participant is expected to complete two sets of questions in an app on a smartphone. This step is done before and after taking the study medicine. The participants must rate:

  • Pain
  • Pain symptoms
  • How the participants are feeling
  • General well-being
03

Conditions studied

  • Migraine

Browse trials for

Keywords

  • CGRP antagonist
  • zavegepant
  • intranasal spray
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants aged 18 years or older.
  2. Participants with minimum 1 year history of migraine with age onset before 50 years of age.

Exclusion criteria

Exclusion Criteria:

  1. History of retinal migraine, basilar migraine or hemiplegic migraine.
  2. History or current evidence of uncontrolled, unstable or recently diagnosed cardiovascular or cardiometabolic disease.
  3. Major depressive disorder or anxiety disorder.
  4. Acute or chronic pain syndromes.
  5. Conditions that may affect the administration or absorption of the nasal product.
  6. History of alcohol abuse and/or illicit drug.
  7. Other social, medical, or psychiatric condition that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  8. Current use of any prohibited concomitant medication(s) or participants unwilling/unable to use a permitted concomitant medication(s)
  9. History of use of ergotamine medications or triptans on greater than/equal to 10 days per month on a regular basis for greater than/equal to 3 months. Or history of non-narcotic analgesic intake on greater than/equal to 15 days per month for greater than/equal to 3 months for other pain indications.
  10. Participation in clinical trial with non-biological agents or interventional treatments (last study visit occurring) within the 30 days prior to Baseline Visit.

    Participation in clinical trial with biological investigational agents (last study visit occurring) within 90 days prior to Baseline Visit. Participation in any other investigational clinical trial while participating in this clinical trial.

  11. Previous participation in any zavegepant study within the last 2 years.
  12. ANY of the following findings at the Screening Visit and laboratory tests as assessed by the study-specific laboratory:

    1. Class 2 or Class 3 obesity, defined as >35 kg/m2.
    2. Estimated Globular Filtration Rate \<30 mL/min/1.73 m2.
    3. Total ≥1.5 × .
    4. Liver transaminases ≥2.0 × upper limit of normal .
    5. ≤1000/μL (or equivalent).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Zavegepant 10 mg

    This is the active arm where the participant will receive 4 doses of the zavegepant 10mg intranasal

    Combination Product: Zavegepant 10 mg

  • Placebo comparator
    Placebo - Control 1

    This is one of the two placebo arms where the participant will receive 3 doses of placebo and 1 dose of zavegepant 10mg intranasal. Participant will not know which dose will be zavegepant.

    Combination Product: Placebo - Control 1

  • Placebo comparator
    Placebo - Control 2

    This is one of the two placebo arms where the participant will receive 3 doses of placebo and 1 dose of zavegepant 10mg intranasal. Participant will not know which dose will be zavegepant.

    Combination Product: Placebo - Control 2

Interventions

  • Combination productZavegepant 10 mg

    4 doses of zavegpant 10 mg intranasal spray device

  • Combination productPlacebo - Control 1

    3 doses of placebo intranasal spray device and 1 dose of zavegepant 10 mg intranasal spray device

  • Combination productPlacebo - Control 2

    3 doses of placebo intranasal spray device and 1 dose of zavegepant 10 mg intranasal spray device

06

What researchers measure

Primary outcomes

  1. Comparing efficacy of zavegepant with placebo in the acute treatment of migraine as measured by pain freedom at 2-hours post dose during the Double-Blind Treatment (DBT) Phase.

    Pain levels will be assessed on a 4-point scale (0=none, 1=mild, 2=moderate, 3=severe) using an electronic handheld device. Pain freedom is measured as a pain level of none at 2 hours post-dose.

    Time frame: 2 hours post-dose

  2. Consistency of efficacy of zavegepant across multiple attacks in the acute treatment of migraine as measured by pain freedom at 2-hours post dose during the DBT Phase.

    Freedom from pain response, defined as pain freedom at 2 hours post-dose in ≥2 of 3 qualifying migraine attacks of moderate to severe in intensity.

    Time frame: 2 hours post-dose

Secondary outcomes

  1. Percentage of participants with freedom from Most Bothersome Symptoms (MBS) at 2 hours post-dose

    Freedom from MBS is defined as the absence of the reported MBS.

    Time frame: 2 hours post-dose

  2. Percentage of participants with pain relief at 2 hours post-dose

    Pain relief is defined as intensity of none or mild.

    Time frame: 2 hours post-dose

  3. Percentage of participants with pain relief at 15 minutes post-dose

    Pain relief is defined as intensity of none or mild.

    Time frame: 15 minutes

  4. Percentage of participants with consistency of pain relief for at least 2 of 3 qualifying attacks at 2 hours post-dose

    Pain relief is defined as intensity of none or mild.

    Time frame: 2 hours post-dose

  5. Percentage of participants with return to normal function at 2 hours post-dose

    Return to normal function is defined as have a functional status of normal.

    Time frame: 2 hours post-dose

  6. Percentage of participants with return to normal function at 30 minutes post-dose

    Return to normal function is defined as have a functional status of normal.

    Time frame: 30 minutes post-dose

  7. Percentage of participants with sustained pain freedom from 2 to 48 hours post-dose

    Pain freedom is measured as a pain level of none. This outcomes measures pain freedom for the duration of 2 to 48 hours post-dose.

    Time frame: 2 to 48 hours post-dose

  8. Percentage of participants in the triptan resistant/refractory (TRR) group with pain freedom at the 2 hours post-dose

    TRR participants are those that have had inadequate responses from at least 2 different triptans as determined by the principal investigator. Pain freedom is measured as a pain level of none.

    Time frame: 2 hours post-dose

  9. Percentage of participants with adverse events (AEs) of moderate or severe intensity

    Time frame: Duration of study (up to 26 weeks from signing of the inform consent to the safety follow-up period.

  10. Percentage of participants with serious adverse events (SAEs)

    Time frame: Duration of study (up to 26 weeks from signing of the inform consent to the safety follow-up period.

  11. Percentage of participants with local irritation AEs

    Time frame: Duration of study (up to 26 weeks from signing of the inform consent to the safety follow-up period.

  12. Percentage of participants with grade 3 or 4 laboratory test abnormalities

    Time frame: Duration of study (up to 26 weeks from signing of the inform consent to the safety follow-up period.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Aug 2027, 22 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2023
First posted
Oct 27, 2023
StartEst.
Sep 15, 2025
Primary completionEst.
Aug 2, 2027
CompletionEst.
Aug 2, 2027
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06103734
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 27, 2023
Start date
Sep 15, 2025 (estimated)
Primary completion
Aug 2, 2027 (estimated)
Completion
Aug 2, 2027 (estimated)
Last update
Jan 13, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zavegepant

Start the discussion